News

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Personalized text message-based smoking cessation intervention was found to be more effective than the non-personalized text message approach, especially among smokers with low nicotine dependence and strong quitting intention.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

Patients with rheumatoid arthritis are at a greater risk of dementia, but why? Take this quiz to test your knowledge of the association between rheumatoid arthritis and dementia.

A systematic review and meta-analysis of 27 studies reveal the prevalence of DR in pediatric T2D increased significantly more than 5 years after diagnosis.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.

Liver stiffness, body weight, and metabolic risk factors were significantly and comparably reduced in both groups.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

Perfluorohexyloctane eye drops demonstrated significantly superior improvements in tCFS and eye dryness scores at day 57 compared with saline.

A remote hypertension management program at Mass General Brigham was associated with significant improvements in blood pressure control despite systemic disruptions in care due to the COVID‐19 pandemic.

While this population was previously thought to be unaffected, studies within the last few years have shown that women with hemophilia experience joint and bleeding problems.

A multinational study provides new insight into the impact of suboptimal sleep duration on risk of incident peripheral artery disease.

There was a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies in the early discontinuer and late discontinuer groups compared to the continuers.

A 13-week trial examining use of the Control-IQ closed-loop insulin delivery system in children aged 2-6 years, results of PEDAP indicate use of the closed-loop system was associated with a 3 hour per day increase in time in range relative to standard care.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.